Healthcare Australian Investing Ideas

AU$0.76
97.1% undervalued intrinsic discount
Fair Value
Profit Margin
29%
Future PE
118x
Price in 2031
AU$1.13
ANN logo
Ansell

Overweight on ANN

My view: Ansell (ASX: ANN) is a quality, mid-risk company suited for a long-term investment. It operates within a stable and expanding TAM, supported by rising global safety and healthcare demand.Read more

View narrative
AU$34.1
11.3% undervalued intrinsic discount
Fair Value
Revenue
8.95% p.a.
Profit Margin
6.74%
Future PE
22.41x
Price in 2031
AU$50.18
AU$199.7
10.4% undervalued intrinsic discount
Fair Value
Revenue
17.32% p.a.
Profit Margin
97.56%
Future PE
59.07x
Price in 2031
AU$294.69
AU$196.78
9.0% undervalued intrinsic discount
Fair Value
Revenue
17.32% p.a.
Profit Margin
97.56%
Future PE
57.87x
Price in 2031
AU$288.69
AU$11.11
57.0% undervalued intrinsic discount
Fair Value
Profit Margin
91%
Future PE
48x
Price in 2029
AU$14.79
AU$1.04
69.2% undervalued intrinsic discount
Fair Value
Profit Margin
13.77%
Future PE
31.32x
Price in 2031
AU$1.53
COH logo
Cochlear

Cochlear’s Crossroads: Temporary Setback or Structural Shift?

Cochlear Limited is an interesting company. It is a medical technology business with a specific focus on implantable hearing solutions.Read more

View narrative
AU$70
62.1% overvalued intrinsic discount
Fair Value
Revenue
0.14% p.a.
Profit Margin
14.77%
Future PE
18.92x
Price in 2031
AU$100.4
AU$133.68
33.9% overvalued intrinsic discount
Fair Value
Revenue
-9.04% p.a.
Profit Margin
53.25%
Future PE
327.23x
Price in 2030
AU$191.26